Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2018 June;43(2) > Minerva Endocrinologica 2018 June;43(2):117-25

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Endocrinologica 2018 June;43(2):117-25

DOI: 10.23736/S0391-1977.16.02553-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Improvement of bone turnover markers and bone mineral density following treatment of primary aldosteronism

Huai H. LOH 1, Nor A. KAMARUDDIN 2, Rozman ZAKARIA 3, Norlela SUKOR 2

1 Faculty of Medicine and Health Sciences, Malaysia Sarawak University, Sarawak, Malaysia; 2 Endocrine Unit, Department of Medicine, National University of Malaysia Medical Center, Selangor, Malaysia; 3 Department of Radiology, National University of Malaysia Medical Center, Selangor, Malaysia


PDF


BACKGROUND: Recent studies showed association between hyperaldosteronism and low bone density among patients with primary aldosteronism (PA) due to secondary hyperparathyroidism. Our objective is to assess bone turnover markers (BTM) and bone mineral density (BMD) of PA patients compared to essential hypertension.
METHODS: This was an open-label, prospective, case-controlled study, conducted over 12 months. Fifty-two consecutive patients referred for secondary hypertension were screened. Eighteen patients with confirmed PA (diagnosis based on the Endocrine Society clinical guideline) and seventeen matched controls with essential hypertension were recruited. BTM (CTX and P1NP), BMD, intact parathyroid hormone (iPTH), and bone profile were assessed at baseline and three months following treatment among the PA patients. Calcium intake was assessed using a validated questionnaire. Primary outcomes were the changes of bone markers and BMD following treatment of PA, and their relation to other parameters.
RESULTS: PA patients had significantly lower serum calcium and higher iPTH despite comparable vitamin D levels with control group. Both BTM were significantly higher among the PA group. BMD of lumbar spine, neck of femur and distal radius did not differ between groups. Three months following treatment, there were significant: 1) reduction in BTM; 2) improvement in the lumbar spine BMD; 3) reduction in iPTH level; and 4) increment of serum 25-OH vitamin D level.
CONCLUSIONS: Our findings support that bone loss and potential fracture risk among PA patients are likely a result of aldosterone-mediated secondary hyperparathyroidism. Patients with early PA may already exhibit increased bone turnover despite no significant changes in BMD.


KEY WORDS: Bone remodeling - Bone density - Osteoporosis - Hyperaldosteronism - Hyperparathyroidism

inizio pagina